565 results on '"Brummer, Tilman"'
Search Results
2. The mTOR pathway controls phosphorylation of BRAF at T401
3. Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors
4. DYRK1A signalling synchronizes the mitochondrial import pathways for metabolic rewiring
5. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease
6. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines
7. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
8. The role of the MDM2/p53 axis in antitumor immune responses
9. Dipeptidyl-peptidase 9 regulates the dynamics of tumorigenesis and metastasis in breast cancer
10. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas
11. Association of RNF43 Genetic Alterations With BRAFV600E and MSIhigh in Colorectal Cancer
12. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma
13. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
14. Association of RNF43 Genetic Alterations With BRAF V600E and MSI high in Colorectal Cancer.
15. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy
16. Enzyme Is the Name – Adapter Is the Game
17. Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
18. Enzyme Is the Name—Adapter Is the Game.
19. Spontaneous activity of the mitochondrial apoptosis pathway drives chromosomal defects, the appearance of micronuclei and cancer metastasis through the Caspase-Activated DNAse
20. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans
21. BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation
22. RAF kinase dimerization: implications for drug discovery and clinical outcomes
23. Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains
24. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts
25. Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery
26. BRaf-Signaling
27. BRAF Somatic Alterations
28. B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model
29. BRAF Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability
30. Supplementary Data from MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production
31. Data from MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production
32. The role of the MDM2/p53 axis in anti-tumor immune responses
33. Immune modulatory effects of oncogenic KRAS in cancer
34. Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling
35. Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
36. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
37. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
38. CDK9‐mediated phosphorylation controls the interaction of TIP60 with the transcriptional machinery
39. RAF-Inhibitoren
40. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production
41. Suppl. Table S2 from A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells
42. Data from A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells
43. Supplementary Figures 1-7 from Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice
44. Supplementary Figures S1-S5 from A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells
45. Supplemental Table Legend from A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells
46. Data from Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice
47. Dissecting the effect of EGF starvation on the signaling and transcriptomic landscapes of the mouse intestinal epithelium
48. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
49. P5 - ASSOCIATION AND INTERACTIONS OF THE RIO KINASES IN THE CONTEXT OF DIAMOND-BLACKFAN ANEMIA
50. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.